Development and validation of a Random Forest prediction model integrating clinical and ultrasound radiomics features for microvascular invasion in hepatocellular carcinoma patients: a retrospective study Authors: Aman Makeshati, Yuying Du, Halida Xiaerfuhazi, Xiaoping Yang Published: 2026 ABSTRACT BackgroundMicrovascular invasion (MVI) is a pivotal driver of postoperative recurrence in hepatocellular carcinoma (HCC), yet its preoperative prediction remains a significant clinical challenge. Accurate preoperative MVI assessment is crucial for guiding surgical decisions, as patients with MVI-positive HCC may benefit from more aggressive resection margins or adjuvant therapies. Existing prediction models based on computed tomography (CT) or magnetic resonance imaging (MRI) radiomics are limited by high cost, limited availability in resource-constrained settings, radiation exposure (for CT), and contraindications (for MRI). In contrast, ultrasound, as the first-line imaging modality for HCC screening, offers unique advantages including real-time imaging capability, cost-effectiveness, portability, no radiation exposure, and widespread availability. However, predictive models based on ultrasound radiomics for MVI remain scarce. This study aimed to develop and validate a Random Forest model integrating clinical characteristics and ultrasound radiomics features for preoperative prediction of MVI in HCC patients.MethodsA total of 224 HCC patients who underwent hepatectomy at the First Affiliated Hospital of Xinjiang Medical University between January 2023 and June 2025 were retrospectively enrolled. Patients were randomly split into training (n=157) and test (n=67) cohorts at a 7:3 ratio. MVI was diagnosed according to the Liver Cancer Pathology Group of China (LCPGC) consensus criteria. After standardizing ultrasound image preprocessing and tumor segmentation, 1,046 radiomic features were extracted. Following feature reduction via 10-fold cross-validated Least Absolute Shrinkage and Selection Operator (LASSO) regression, three machine learning models [Random Forest, backpropagation neural network (BPNN), and Nomogram] were developed and compared.ResultsThe study cohort comprised 224 patients (mean age 57.9±6.2 years; 70.5% male), with MVI confirmed in 74 patients (33.0%). Patients were randomly split into training (n=157, MVI 31.8%) and test (n=67, MVI 35.8%) cohorts at a 7:3 ratio. Multivariate analysis identified maximum tumor diameter, alpha-fetoprotein (AFP), and vascular endothelial growth factor (VEGF) as independent clinical predictors of MVI (all P<0.05). LASSO regression selected four robust radiomics features. In the test cohort, the Random Forest model achieved an area under the receiver operating characteristic curve (AUC) of 0.908, with sensitivity of 79.2%, specificity of 81.4%, and accuracy of 80.6%, significantly outperforming both the BPNN model (AUC =0.675) and Nomogram model (AUC =0.755). Decision curve analysis confirmed the higher clinical utility of the Random Forest model.ConclusionsThe Random Forest model integrating clinical characteristics and ultrasound radiomics features demonstrated favorable predictive performance for the preoperative assessment of MVI in HCC patients. However, given the retrospective, single-center design and relatively small sample size, these findings should be interpreted with caution. This model holds potential as a cost-effective, noninvasive tool to support individualized surgical planning. Further external validation in multi-center cohorts is warranted before clinical implementation. Highlight box Key findings • A Random Forest model integrating three clinical predictors (maximum tumor diameter, alpha-fetoprotein, and vascular endothelial growth factor) and four ultrasound radiomic features achieved an area under the receiver operating characteristic curve (AUC) of 0.908 for preoperative prediction of microvascular invasion (MVI) in hepatocellular carcinoma (HCC) patients, significantly outperforming backpropagation neural network and nomogram models. What is known and what is new? • MVI is an independent predictor of early postoperative recurrence and poor survival in HCC. Existing prediction models based on computed tomography (CT) or magnetic resonance imaging (MRI) radiomics are limited by high cost, radiation exposure, and contraindications. • This study is among the first to develop a Random Forest model combining clinical features and ultrasound radiomic features for preoperative MVI prediction. Ultrasound, as the first-line imaging modality for HCC screening, provides a cost-effective and noninvasive alternative to CT/MRI-based approaches. What is the implication, and what should change now? • This model offers a practical, noninvasive tool to support individualized surgical planning for HCC patients. Multi-center external validation is needed before clinical implementation. Introduction Hepatocellular carcinoma (HCC) is the sixth most common malignancy worldwide and one of the five most prevalent cancers in China. Approximately 400,000 new cases of HCC are diagnosed annually in China, and its mortality rate ranks second among all malignant tumors, following only lung cancer (1,2). Surgical resection remains the preferred curative treatment for HCC; however, the recurrence rate within five years after radical hepatectomy is as high as 50–70%, and that after liver transplantation is approximately 15–30% (3,4). HCC is highly prone to vascular invasion, leading to hematogenous metastasis, which is considered one of the primary causes of postoperative recurrence and metastasis (3,4). Microvascular invasion (MVI) refers to microscopic clusters of tumor cells found within small vessels lined by endothelial cells, typically located in the tumor capsule or within the peritumoral liver parenchyma, especially in small branches of the portal vein. Previous studies have reported that the incidence of MVI in HCC ranges from 15% to 57% (5). MVI is recognized as an independent predictor of early postoperative recurrence, metastasis, and poor overall survival in HCC patients, and its biological and prognostic significance has received increasing attention (6). Preoperative assessment of MVI is clinically valuable, as it can help determine appropriate surgical margins, optimize candidate selection for liver transplantation, and guide individualized surgical decision-making in patients with small HCC (7). Therefore, MVI is currently regarded as the most important pathological feature for guiding the prevention and management of HCC recurrence. Accurate and effective preoperative prediction of MVI is crucial for improving postoperative survival outcomes in HCC patients. However, the diagnosis of MVI relies on histopathological examination of surgically resected specimens rather than preoperative biopsy samples. Postoperative pathological assessment is inherently retrospective, limiting its utility for preoperative and intraoperative decision-making. This underscores the necessity and clinical importance of accurately predicting MVI before surgery. Given this clinical need, researchers have explored various approaches for preoperative MVI assessment. At present, predictive factors include clinical characteristics, serological indicators, imaging features, and radiomics features (8). Zhang et al. (9) developed a nomogram model based on five parameters—maximum tumor diameter, tumor number, tumor capsule, alpha-fetoprotein (AFP) level, and imaging characteristics—achieving an area under the receiver operating characteristic curve (AUC) of 0.811, with a sensitivity of 73.5% and specificity of 76.6%. Similarly, Qu et al. (10) constructed a support vector machine model using high-dimensional radiomics features extracted from computed tomography (CT)/magnetic resonance imaging (MRI) images via Least Absolute Shrinkage and Selection Operator (LASSO) regression analysis, yielding an AUC of 0.836 for predicting MVI in HCC patients. However, these existing models face several limitations. MRI-based models are constrained by high cost, limited availability in resource-constrained settings, and contraindications in patients with metallic implants or renal dysfunction (11). CT-based radiomics models, while more widely available, expose patients to ionizing radiation and require iodinated contrast agents that carry nephrotoxicity risks (11). Moreover, previous studies (9-11) generally suffer from small sample sizes, suboptimal predictive performance, lack of external validation, and inconsistent inclusion criteria. To date, few models have been developed based on ultrasound radiomics features for predicting MVI risk in HCC patients. In comparison, ultrasound radiomics offers unique advantages for MVI prediction: (I) real-time imaging capability allowing dynamic assessment of tumor characteristics; (II) cost-effectiveness making it accessible in primary care settings and resource-limited regions; (III) portability enabling bedside examinations for critically ill patients; (IV) no radiation exposure, permitting repeated assessments during treatment monitoring; and (V) widespread availability as the first-line imaging modality for HCC screening in China and many developing countries. Despite these advantages, few studies have systematically evaluated ultrasound radiomics for MVI prediction, representing a significant knowledge gap that our study aims to address. To address these gaps, this study aimed to construct a Random Forest model integrating both clinical characteristics and ultrasound radiomics features to predict the risk of MVI in HCC patients. Random Forest, an ensemble learning algorithm, was chosen as the primary algorithm due to several advantages: (I) ability to handle high-dimensional radiomic features with relatively small sample sizes without extensive feature preprocessing; (II) capability to capture complex nonlinear relationships and feature interactions inherent in multimodal clinical and imaging data; (III) built-in feature importance estimation that facilitates interpretation of model predictions; (IV) resistance to overfitting through bootstrap aggregation and random feature selection; and (V) robustness against outliers and noise commonly present in real-world clinical data. In contrast, backpropagation neural network (BPNN) was selected as a comparison algorithm to represent the deep learning approach, as it can learn complex patterns through multiple hidden layers and has shown promising performance in various medical prediction tasks. By comparing these two distinct algorithmic approaches, we aimed to identify which machine learning paradigm is more suitable for ultrasound radiomics-based MVI prediction in HCC patients, thereby providing evidence-based guidance for future model development in this field. This approach may assist clinicians in accurately assessing MVI risk before surgery, enabling individualized surgical planning, reducing postoperative recurrence and metastasis, and ultimately improving the overall survival of HCC patients. We present this article in accordance with the TRIPOD reporting checklist (available at https://tcr.amegroups.com/article/view/10.21037/tcr-2026-1-0031/rc). Methods Study population A total of 224 HCC patients who received treatment at the First Affiliated Hospital of Xinjiang Medical University between January 2023 and June 2025 were retrospectively enrolled in this study. The patients were randomly divided into a training cohort (n=157, 70.1%) and a test cohort (n=67, 29.9%) at a ratio of 7:3. Sample size calculation: the required sample size was calculated using the formula: N = (k × EPV)/p, where k represents the number of predictor variables (k=7, including 3 clinical predictors and 4 radiomics features), EPV denotes the events per variable (EPV =10, recommended minimum), and p indicates the expected MVI positive rate (p=0.33). The calculated minimum sample size was 212 patients. Our final sample of 224 patients exceeded this requirement. The test cohort represents an internal validation set from random splitting of the single-center dataset, rather than an independent external validation cohort. Inclusion criteria: (I) age >18 years; (II) good general physical condition and eligible for hepatectomy; (III) preoperative imaging and postoperative histopathological examination confirming the diagnosis of HCC; (IV) postoperative histopathological confirmation of MVI. Exclusion criteria: (I) evidence of major vascular tumor thrombus, invasion of adjacent organs, or distant metastasis on preoperative CT/MRI; (II) Child-Pugh classification was C; (III) severe cardiac, pulmonary, or renal insufficiency; (IV) coexisting hematological or autoimmune diseases; (V) presence of other primary malignant tumors; (VI) presence of acute infectious diseases; (VII) incomplete case data. This study was conducted in accordance with the Declaration of Helsinki and its subsequent amendments. The study was approved by the Ethics Committee of The First Affiliated Hospital of Xinjiang Medical University (No. K202309-12-2409A-Y3). Written informed consent was obtained from all participants for study enrollment and data analysis. Clinical data collection (I) Baseline clinical information, including age, sex, body mass index (BMI), presence of liver cirrhosis, and diabetes, was recorded upon admission for all HCC patients. (II) On the morning of the second day after admission, 5 mL of fasting venous blood was collected from each patient, centrifuged at 3,000 r/min for 10 minutes, and the serum supernatant was stored at −80 ℃ until further analysis. Serum AFP, vascular endothelial growth factor (VEGF), and C-reactive protein (CRP) levels were measured using enzyme-linked immunosorbent assay (ELISA). Hepatitis B surface antigen (HBsAg), alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transpeptidase (GGT), albumin, and total bilirubin levels were measured using a chemiluminescence assay. Routine hematological parameters, including neutrophil count, lymphocyte count, and platelet count, were determined using electrical impedance and laser scattering techniques. The neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) were calculated as follows: NLR = neutrophil count/lymphocyte count, PLR = platelet count/lymphocyte count. (III) Ultrasound imaging data were recorded for each patient, including maximum tumor diameter, echogenicity, tumor number, and tumor capsule status. (IV) Postoperative pathological diagnosis and the presence or absence of MVI were documented for all patients. MVI pathological diagnosis MVI was defined as the presence of microscopic tumor cell clusters within endothelium-lined vascular spaces in the tumor capsule or peritumoral liver parenchyma. The histopathological diagnosis strictly followed the Liver Cancer Pathology Group of China (LCPGC) consensus criteria [2019]. According to LCPGC criteria, MVI was classified as M0 (no MVI), M1 (1–5 MVI foci), or M2 (>5 MVI foci) (12). For this study, M1 and M2 were combined as MVI-positive. Surgical specimens were fixed in 10% neutral buffered formalin for 24–48 hours, embedded in paraffin, and sectioned at 4-µm thickness for hematoxylin and eosin (H&E) staining. Multiple tissue sections from the tumor-liver interface were obtained. All pathological assessments were performed by two experienced hepatobiliary pathologists (with 10 and 15 years of experience) who were blinded to clinical and imaging data. Disagreements were resolved through joint review. Ultrasound image acquisition and lesion segmentation All HCC patients underwent ultrasound examination using a Samsung R10 color Doppler ultrasound diagnostic system equipped with a CA1-7A convex array probe operating at a frequency of 3–5 MHz. Liver morphology, size, internal echogenicity, and intrahepatic and extrahepatic bile duct diameters were evaluated to obtain high-quality tumor ultrasound images. The acquired ultrasound images were imported into ITK-SNAP software for further processing. The region of interest (ROI) was manually delineated along the tumor boundary on the maximum cross-sectional image of the lesion to achieve precise lesion segmentation. Both ultrasound image acquisition and lesion segmentation were performed by a radiologist with 10 years of experience in liver ultrasound diagnostics to ensure consistency and accuracy. Ultrasound radiomics feature extraction Four image filters (wavelet, square, exponential, and gradient) were applied to the original ultrasound images of each patient to generate corresponding derived images. Radiomic features were extracted from both the original and filtered images using Pyradiomics version 3.0.1. A total of 1,046 ultrasound radiomics features were obtained, encompassing first-order statistics, shape features, gray-level co-occurrence matrix, gray-level run length matrix, gray-level size zone matrix, neighboring gray tone difference matrix, and gray-level dependence matrix features. Missing feature values were imputed using the median value. To eliminate the influence of dimensional differences and ensure the comparability and uniform distribution of radiomic features, all 1,046 features were normalized using an improved MinMaxScaler algorithm. Statistical analysis Construction of the Nomogram model Statistical analyses of the general clinical characteristics of HCC patients in the training cohort were performed using SPSS version 26.0 and R version 4.5.1. Categorical variables were expressed as n (%) and compared between groups using the χ2 test. Continuous variables following a normal distribution were presented as mean ± standard deviation and compared using the independent samples t-test. Continuous variables with a non-normal distribution were expressed as median [interquartile range (IQR)] and analyzed using the Mann-Whitney U test. Variables with statistical significance in the univariate analysis were further included in a multivariate logistic regression analysis. The forward likelihood ratio method was used to identify independent predictors of MVI in HCC patients. Based on these independent predictors, a Nomogram model for preoperative prediction of MVI was constructed using the “rms” package in R. A P value <0.05 was considered statistically significant. Construction of the BPNN model The ultrasound radiomics features of HCC patients in the training cohort were analyzed using R version 4.5.1. To reduce dimensionality and select the most representative features, 10-fold cross-validated LASSO regression was performed using the “caret” and “glmnet” packages. This process was applied to all 1,046 ultrasound radiomics features extracted from the training dataset. Based on the finally selected radiomics features, a BPNN model was constructed using the “neuralnet” package in R. Cross-validation and grid search methods were employed for hyperparameter optimization, and the best-performing parameters were selected for model training. The BPNN model was trained to minimize the following loss function: J(xi,yi)=12m∑i=1m(yi−h0(xi))2. The multilayer feedforward neural network was trained using the backpropagation gradient descent algorithm, which iteratively updated and optimized the weights of each feature variable to achieve the minimum prediction error. Construction of the Random Forest model The clinical characteristics and ultrasound radiomics features of HCC patients in the training cohort were analyzed using R version 4.5.1. Based on the clinical features identified through multivariate logistic regression analysis and the ultrasound radiomics features selected by 10-fold cross-validated LASSO regression, a Random Forest model was constructed using the “randomForest” package in R. The out-of-bag (OOB) error rate, including the misclassification rates of different outcome events and the overall error rate, was used to evaluate the stability of the Random Forest model. The importance of each variable in the model was assessed using two approaches: the Mean Decrease Accuracy index and the Mean Decrease Gini index. Model evaluation and validation Statistical analyses were performed using SPSS version 26.0 and R version 4.5.1. The predictive performance of the constructed models was evaluated in both the training and testing cohorts. The predictive efficiency of each model was assessed based on the area under the receiver operating characteristic curve (AUC), sensitivity, specificity, accuracy, precision, and F1-score. The corresponding evaluation metrics were defined as follows: sensitivity = true positive/(true positive + false negative), specificity = true negative/(true negative + false positive), accuracy = (true positive + true negative)/(true positive + true negative + false positive + false negative), precision=true positive/(true positive + false positive), F1-score = 2 × sensitivity × precision/(sensitivity + precision). Additionally, Decision curve analysis was performed to evaluate the clinical utility of each predictive model by quantifying the net benefit across a range of threshold probabilities. Model calibration was evaluated using calibration plots with 10 quantile bins to assess the agreement between predicted probabilities and observed outcomes of MVI. The Brier score, ranging from 0 to 1 (lower values indicate better calibration), was calculated to quantify calibration performance, as shown in Figure 1. Experimental technical route. Experimental technical route delineated the clinical research design, encompassing patient enrollment criteria, group allocation strategies, experimental methodologies, and research objectives. AUC, area under the receiver operating characteristic curve; BPNN, backpropagation neural network; HCC, hepatocellular carcinoma; LASSO, Least Absolute Shrinkage and Selection Operator; MVI, microvascular invasion; N-MVI, non-microvascular invasion; OOB, out-of-bag. Results Comparison of baseline clinical characteristics between the training and test cohorts This study included 224 HCC patients. The patients ranged in age from 45 to 73 years, with a mean age of 57.9±6.2 years. The cohort comprised 158 males (70.5%) and 66 females (29.5%). MVI was confirmed in 74 patients (33.0%). In the training cohort, the age range was 45–72 years (mean 58.0±6.1 years), with 108 males (68.8%) and 49 females (31.2%), MVI was present in 50 patients (31.8%). The test cohort had an age range of 45–73 years (mean 57.8±6.5 years), with 50 males (74.6%) and 17 females (25.4%), MVI was identified in 24 patients (35.8%). No statistically significant differences were observed between the training and test cohorts regarding age, sex, BMI, HBsAg status, cirrhosis, diabetes, Child-Pugh classification, tumor number, tumor capsule, tumor echogenicity, or MVI status (all P>0.05), as presented in Table 1. Table 1Comparison of general clinical characteristics of HCC patients in the training and test cohortsVariableTraining cohort (n=157)Test cohort (n=67)t/χ2PAge (years)58.0±6.157.8±6.5t=0.1750.86Gender (male/female)108/4950/17χ2=0.5150.47BMI (kg/m2)22.7±2.322.5±2.3t=0.5590.57HBsAg (positive/negative)115/4247/20χ2=0.0970.75Cirrhosis (yes/no)117/4045/22χ2=0.9290.33Diabetes (yes/no)34/12313/54χ2=0.0400.84Child-Pugh (Grade A/Grade B)70/7730/37χ2=0.0570.81Tumor number (single/multiple)114/4340/27χ2=3.0670.08Tumor capsule (present/absent)92/6541/26χ2=0.0460.83Tumor echogenicity (hypoechoic/hyperechoic)113/4452/15χ2=0.5060.47MVI (yes/no)50/10724/43χ2=0.1800.67Data are presented as mean ± standard deviation or number. BMI, body mass index; HBsAg, hepatitis B surface antigen; HCC, hepatocellular carcinoma; MVI, microvascular invasion. Comparison of general clinical characteristics of HCC patients in the training and test cohorts Data are presented as mean ± standard deviation or number. BMI, body mass index; HBsAg, hepatitis B surface antigen; HCC, hepatocellular carcinoma; MVI, microvascular invasion. Comparison of clinical characteristics between HCC patients with and without MVI in the training cohort To preliminarily identify clinical characteristics associated with MVI in HCC patients, the training cohort (n=157) was stratified into two groups based on MVI status: the non-MVI group (N-MVI, n=107, 68.2%) and the MVI group (n=50, 31.8%). The MVI group exhibited significantly larger maximum tumor diameter, higher AFP levels, and elevated VEGF levels compared to the N-MVI group (all P<0.05). However, no statistically significant differences were found between the two groups in terms of age, sex, BMI, HBsAg status, liver cirrhosis, diabetes, Child-Pugh classification, tumor number, tumor capsule, tumor echogenicity, GGT, NLR, PLR, or CRP (all P>0.05), as presented in Table 2. Table 2Comparison of general clinical characteristics between the two groups of HCC patients in the training cohortVariableN-MVI (n=107)MVI (n=50)t/χ2PAge (years)58.2±5.757.4±6.7t=0.6720.50Gender (male/female)70/3738/12χ2=1.3180.25BMI (kg/m2)22.8±2.222.4±2.5t=1.1620.24HBsAg (positive/negative)75/3240/10χ2=1.2360.26Cirrhosis (yes/no)76/3141/9χ2=1.6210.20Diabetes (yes/no)20/8714/36χ2=1.2350.26Child-Pugh (Grade A/Grade B)50/5720/30χ2=0.3820.53Maximum tumor size (cm)4.6±1.36.3±1.3t=7.342<0.001Tumor number (single/multiple)80/2734/16χ2=0.4810.48Tumor capsule (present/absent)67/4025/25χ2=1.7460.18Tumor echogenicity (hypoechoic/hyperechoic)75/3238/12χ2=0.3330.56GGT (U/L)110.95±22.33112.25±26.09t=0.3050.76AFP (μg/L)17.89±5.6625.82±8.10t=7.090<0.001VEGF (pg/mL)111.67±25.35151.67±37.54t=6.840<0.001NLR4.56±0.994.61±1.11t=0.2290.82PLR269.26±27.26275.90±33.27t=1.2300.22CRP (mg/L)5.57±1.085.47±1.31t=0.4650.64Data are presented as mean ± standard deviation or number. AFP, alpha-fetoprotein; BMI, body mass index; CRP, C-reactive protein; GGT, gamma-glutamyl transpeptidase; HBsAg, hepatitis B surface antigen; HCC, hepatocellular carcinoma; MVI, microvascular invasion; N-MVI, non-microvascular invasion; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; VEGF, vascular endothelial growth factor. Comparison of general clinical characteristics between the two groups of HCC patients in the training cohort Data are presented as mean ± standard deviation or number. AFP, alpha-fetoprotein; BMI, body mass index; CRP, C-reactive protein; GGT, gamma-glutamyl transpeptidase; HBsAg, hepatitis B surface antigen; HCC, hepatocellular carcinoma; MVI, microvascular invasion; N-MVI, non-microvascular invasion; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; VEGF, vascular endothelial growth factor. Multivariate logistic regression analysis for MVI in the training cohort of HCC patients To further identify independent predictors for MVI in HCC patients, variables that showed statistical significance in the univariate analysis of the training cohort—specifically, maximum tumor diameter (actual value), AFP (actual value), and VEGF (actual value)—were incorporated into a multivariate logistic regression model. After adjusting for potential confounding variables, maximum tumor diameter, AFP, and VEGF remained independent predictors of MVI in HCC patients (P<0.05), as presented in Table 3. Table 3Multivariate logistic regression analysis for predicting MVI in HCC patients from the training cohortVariableβSEWaldPOR95% CIAFP0.1290.03910.9990.0011.1381.054–1.228VEGF0.0200.0103.8330.0491.0201.000–1.041Maximum tumor size0.4080.2034.0440.0441.5041.010–2.240Constant−8.2651.26542.687<0.001––AFP, alpha-fetoprotein; CI, confidence interval; HCC, hepatocellular carcinoma; MVI, microvascular invasion; OR, odds ratio; SE, standard error; VEGF, vascular endothelial growth factor. Multivariate logistic regression analysis for predicting MVI in HCC patients from the training cohort AFP, alpha-fetoprotein; CI, confidence interval; HCC, hepatocellular carcinoma; MVI, microvascular invasion; OR, odds ratio; SE, standard error; VEGF, vascular endothelial growth factor. Construction of the Nomogram model To develop a nomogram model based on general clinical characteristics, three clinical features identified through multivariate logistic regression analysis—maximum tumor diameter, AFP, and VEGF—were incorporated along with their respective weight values (β coefficients) from the multivariate analysis. A Nomogram model for predicting the risk of MVI in HCC patients was constructed as follows: Nomogram score =0.129 × AFP (µg/L) + 0.020 × VEGF (pg/mL) + 0.408 × maximum tumor diameter (cm) − 8.265, as shown in Figure 2. Nomogram model based on maximum tumor diameter, AFP, and VEGF for predicting MVI risk. To use the nomogram, locate each patient’s value for every variable on the corresponding axis. Draw a vertical line upward from that value to the “Points” axis to determine the score for that variable. Sum the scores of all variables to obtain the total points. Finally, locate the total points on the “Total Points” axis and draw a vertical line downward to the “Risk” axis to read the predicted probability of MVI for the patient. AFP, alpha-fetoprotein; MVI, microvascular invasion; VEGF, vascular endothelial growth factor. Selection of ultrasound radiomic features To identify radiomic features predictive of MVI in HCC patients, a 10-fold cross-validated LASSO regression analysis was performed on 1,046 ultrasound radiomic features in the training set for dimensionality reduction and feature selection. Four radiomic features with the strongest generalizability were ultimately selected: wavelet_lll_glrlm_runentropy, wavelet_lll_glcm_correlation, wavelet_lll_glcm_imc1, and wavelet_lll_lbp.3D.m1_firstorder_Maximum, with corresponding coefficient values of 0.366, 0.215, 0.228, and 0.315, respectively, as shown in Figures 3,4. Dimensionality reduction plot of 10-cross-validated LASSO regression. The figure illustrates the variation in prediction error with respect to log(lambda). The error bars along the curve reflect the stability of model performance. The right vertical dashed line indicates the log(lambda) value corresponding to the minimum prediction error, while the left vertical dashed line represents the optimal log(lambda) selected based on the one-standard-error rule. In this study, the four selected ultrasound radiomic features correspond to this optimal log(lambda). LASSO, Least Absolute Shrinkage and Selection Operator. LASSO regression coefficient path plot. The figure displays the coefficient paths of variables as the regularization parameter log(lambda) changes. This study selected the coefficient values of the four ultrasound radiomic features corresponding to the optimal log(lambda). LASSO, Least Absolute Shrinkage and Selection Operator. Construction of the BPNN model To develop a BPNN model based on radiomic features, four ultrasound radiomic features selected via 10-fold cross-validated LASSO regression were used to construct a BPNN for predicting MVI risk in HCC patients. Hyperparameter tuning was performed using cross-validation and grid search. The optimal parameters identified were as follows: a network topology of 4–5–2 [hidden = c(5)], a maximum of 107 iterations (stepmax =107), and a learning rate of 0.5 (learningrate =0.5). The model achieved the minimum loss value of 8.524463 after 18,470 weight update iterations, indicating optimal convergence, as shown in Figure 5. BPNN model. The BPNN model was constructed using four input neurons corresponding to the features: wavelet_lll_glrlm_runentropy, wavelet_lll_glcm_correlation, wavelet_lll_glcm_imc1, and wavelet_lll_lbp.3D.m1_firstorder_Maximum. The hidden layer contained five neurons, while the output layer consisted of two neurons representing MVI and N-MVI, respectively. The model was trained using backpropagation with gradient descent to adjust the weights. In the diagram, values on the black arrows indicate connection weights between neurons, and values on the blue arrows represent bias weights. BPNN, backpropagation neural network; MVI, microvascular invasion; N-MVI, non-microvascular invasion. Construction of the Random Forest model To develop a Random Forest model based on general clinical features and ultrasound radiomic features, three clinical features selected by multivariate logistic regression analysis and four ultrasound radiomic features selected by 10-fold cross-validated LASSO regression were incorporated. During the modeling process, approximately one-third of the training set was used as OOB data. The final model consisted of 1,000 decision trees (ntree =1,000, mtry =3, nodesize =10). The OOB error rates for predicting MVI-positive, MVI-negative, and overall cases stabilized at 26.0%, 5.6%, and 12.1%, respectively. Both the three clinical features and the four ultrasound radiomic features contributed significantly to predicting MVI status in HCC patients, as shown in Figures 6,7. Structure diagram of the Random Forest model. The figure shows the variation in OOB prediction error rates with the number of decision trees. The green curve represents the OOB error rate for predicting HCC patients with MVI, the red curve denotes the OOB error rate for predicting HCC patients without MVI, and the black curve indicates the overall OOB prediction error rate. HCC, hepatocellular carcinoma; MVI, microvascular invasion; OOB, out-of-bag. Feature importance plot based on mean decrease accuracy and mean decrease Gini. The figure illustrates the importance scores of the three clinical features and four ultrasound radiomic features in the Random Forest model, as evaluated by the mean decrease in accuracy and the mean decrease in Gini index, respectively. A higher value indicates a greater contribution of the variable to the model. AFP, alpha-fetoprotein; VEGF, vascular endothelial growth factor. ROC curve analysis To evaluate the predictive performance of the three distinct machine learning models, ROC curve analysis was employed. In the training cohort, the Random Forest model achieved an AUC of 0.999 [95% confidence interval (CI): 0.997–1.000] for predicting MVI in HCC patients, which was higher than that of the BPNN model (AUC =0.958, 95% CI: 0.922–0.955) and the Nomogram model (AUC =0.861, 95% CI: 0.793–0.929). In the test cohort, the Random Forest model also showed superior performance with an AUC of 0.908 (95% CI: 0.839–0.978), compared to the BPNN model (AUC =0.675, 95% CI: 0.524–0.827) and the Nomogram model (AUC =0.755, 95% CI: 0.633–0.876), as shown in Figures 8,9. ROC curves of three machine learning models for predicting MVI in HCC patients in the training cohort. The figure shows that the AUC for predicting MVI in HCC patients were 0.999 (95% CI: 0.997–1.000) for the Random Forest model, 0.958 (95% CI: 0.922–0.995) for the BPNN model, and 0.861 (95% CI: 0.793–0.929) for the Nomogram model. AUC, area under the ROC curve; BPNN, backpropagation neural network; CI, confidence interval; HCC, hepatocellular carcinoma; MVI, microvascular invasion; ROC, receiver operating characteristic. ROC curves of three machine learning models for predicting MVI in HCC patients in the test cohort. The figure demonstrates that the AUC for predicting MVI in HCC patients were 0.908 (95% CI: 0.839–0.978) for the Random Forest model, 0.675 (95% CI: 0.524–0.827) for the BPNN model, and 0.755 (95% CI: 0.633–0.876) for the Nomogram model. AUC, area under the ROC curve; BPNN, backpropagation neural network; CI, confidence interval; HCC, hepatocellular carcinoma; MVI, microvascular invasion; ROC, receiver operating characteristic. Decision curve analysis To evaluate the clinical utility of the three machine learning models, decision curve analysis was performed. In both the training and test cohorts, the Random Forest model demonstrated higher net benefit for predicting MVI in HCC patients compared to the BPNN and Nomogram models across most of the high-risk threshold range of 0–1.0, as shown in Figures 10,11. Decision curves of three machine learning models for predicting MVI in HCC patients in the training cohort. The x-axis and y-axis represent the high-risk threshold and net benefit, respectively. The gray line represents the assumption that all patients have MVI, while the horizontal black line denotes the assumption that no patients have MVI. The figure shows that the Random Forest model provides higher net benefit compared to both the BPNN model and the Nomogram model. BPNN, backpropagation neural network; HCC, hepatocellular carcinoma; MVI, microvascular invasion. Decision curves of three machine learning models for predicting MVI in HCC patients in the test cohort. The x-axis and y-axis represent the high-risk threshold and net benefit, respectively. The gray line indicates the assumption that all patients have MVI, and the horizontal black line represents the assumption that no patients have MVI. The results demonstrate that the Random Forest model yields higher net benefit than both the BPNN model and the Nomogram model. BPNN, backpropagation neural network; HCC, hepatocellular carcinoma; MVI, microvascular invasion. Calibration curve analysis Calibration curves were generated to assess the agreement between predicted probabilities and observed outcomes of MVI for all three models. The Brier score, ranging from 0 to 1 (lower values indicate better calibration), was used to quantify calibration performance. In the training cohort, the Random Forest model demonstrated excellent calibration with the lowest Brier score of 0.028, indicating strong agreement between predicted probabilities and actual MVI rates. The BPNN model showed good calibration (Brier score: 0.054), while the Nomogram model exhibited acceptable calibration (Brier score: 0.127). In the test cohort (n=67), the Random Forest model maintained good calibration performance with a Brier score of 0.117, confirming its generalizability to independent data. The Nomogram model (Brier score: 0.203) and BPNN model (Brier score: 0.233) showed acceptable calibration in the test cohort. The consistent calibration performance across both cohorts suggests that the Random Forest model provides reliable probability estimates suitable for clinical decision-making, as shown in Figures 12,13. Calibration curves for three machine learning models in the training cohort. The x-axis represents the mean predicted probability of MVI, and the y-axis represents the actual fraction of MVI-positive patients. The diagonal dashed line represents perfect calibration, where predicted probabilities exactly match observed outcomes. The Random Forest model (orange triangles) demonstrated excellent calibration with the lowest Brier score of 0.028, indicating superior agreement between predicted and observed MVI rates. The BPNN model (purple circles) showed good calibration (Brier score: 0.054), and the Nomogram model (blue squares) exhibited acceptable calibration (Brier score: 0.127). Closer alignment of the model curves with the diagonal line indicates better calibration performance. The Brier score represents the mean squared difference between predicted probabilities and actual outcomes, with lower values indicating better calibration. BPNN, backpropagation neural network; MVI, microvascular invasion. Calibration curves for three machine learning models in the test cohort. The x-axis represents the mean predicted probability of MVI, and the y-axis represents the actual fraction of MVI-positive patients. The diagonal dashed line represents perfect calibration. The Random Forest model (orange triangles) maintained good calibration performance in the independent test cohort with a Brier score of 0.117, demonstrating the model’s generalizability. The Nomogram model (blue squares) showed acceptable calibration (Brier score: 0.203), and the BPNN model (purple circles) exhibited moderate calibration (Brier score: 0.233). The slightly higher Brier scores in the test cohort compared to the training cohort reflect the expected optimism bias in model development, yet the Random Forest model’s performance remains clinically acceptable. These results confirm that the Random Forest model provides well-calibrated probability estimates that can inform individualized surgical planning for HCC patients. BPNN, backpropagation neural network; HCC, hepatocellular carcinoma; MVI, microvascular invasion. Predictive performance evaluation of the three machine learning models To assess the predictive performance of the three machine learning models, sensitivity, specificity, accuracy, precision, and F1-score were calculated. The optimal probability threshold for each model was determined using the Youden index (maximum sensitivity + specificity − 1) in the training cohort. For the Random Forest model, the optimal cut-off value was 0.400, yielding a sensitivity of 79.2% (95% CI: 60.8–87.2%) and specificity of 81.4% (95% CI: 70.5–88.9%) in the test cohort. For the BPNN model, the optimal cut-off was 0.184, and for the Nomogram model, the optimal cut-off was 0.260. In both the training and test cohort, the Random Forest model demonstrated higher values across all metrics—sensitivity, specificity, accuracy, precision, and F1-score—compared to both the BPNN model and the Nomogram model, as presented in Table 4. Table 4Sensitivity, specificity, accuracy, precision, and F1-score of different machine learning modelsModelGroupSensitivity (95% CI)Specificity (95% CI)Accuracy (95% CI)Precision (95% CI)F1-score (95% CI)Nomogram modelTraining cohort0.840 (0.775–0.889)0.803 (0.735–0.858)0.815 (0.747–0.868)0.667 (0.590–0.736)0.743 (0.670–0.805)Test cohort0.750 (0.635–0.838)0.535 (0.417–0.649)0.612 (0.492–0.720)0.474 (0.359–0.591)0.581 (0.461–0.691)BPNN modelTraining cohort0.920 (0.867–0.953)0.9160 (0.862–0.950)0.917(0.864–0.951)0.836 (0.771–0.886)0.876 (0.816–0.919)Test cohort0.500 (0.384–0.616)0.744 (0.629–0.833)0.657 (0.537–0.759)0.522 (0.404–0.637)0.511(0.394–0.627)Random Forest modelTraining cohort1.000 (0.976–1.000)0.981 (0.946–0.994)0.987 (0.955–0.997)0.962 (0.919–0.982)0.980 (0.945–0.993)Test cohort0.792 (0.680–0.872)0.814 (0.705–0.889)0.806 (0.696–0.883)0.704 (0.586–0.800)0.745 (0.630–0.834)BPNN, backpropagation neural network; CI, confidence interval. Sensitivity, specificity, accuracy, precision, and F1-score of different machine learning models BPNN, backpropagation neural network; CI, confidence interval. Discussion While mortality rates for HCC have shown a declining trend in recent years—attributed to advances in targeted therapy, immune-based medications, surgical techniques, and comprehensive treatment strategies—HCC remains the second leading cause of cancer-related death in China (1,2). Following radical resection, the 5-year recurrence and metastasis rate of HCC is as high as 50–70%, with an overall survival rate of less than 20%. One critical factor underlying this poor prognosis is the presence of MVI confirmed by postoperative pathology. MVI positivity typically indicates a highly aggressive tumor phenotype with strong metastatic potential, leading to high postoperative recurrence and poor overall survival (5,6). However, the diagnosis of MVI currently relies mainly on postoperative histopathological examination, which limits its utility in guiding individualized clinical decision-making prior to surgery. Therefore, developing more efficient preoperative prediction methods is of significant clinical value for optimizing surgical guidance and improving survival outcomes. As an emerging non-invasive diagnostic method in medicine, radiomics is a computer-assisted technique that converts medical information into a series of quantifiable data, aiding in the extraction of features undetectable by the human eye from high-throughput quantitative images (13,14). In recent years, there has been growing interest in the relationship between radiomic features and tumor characteristics (13-16). Previous studies (13-16) have shown that radiomic features can reflect tumor texture information, malignant biological behavior, microstructure, and intratumoral heterogeneity. Research by Zhang et al. (17) and Chen et al. (18) demonstrated that MRI-based radiomic models achieved AUCs of 0.781 and 0.820, respectively, in predicting cytokeratin 19 (CK19) positive expression in HCC patients, indicating the favorable diagnostic performance of MRI radiomics for identifying CK19-positive HCC. Other studies have shown that models built on radiomic features not only perform well in predicting HCC differentiation grade (19), but also show good efficacy in assessing the expression levels of biomarkers such as Ki-67 (20) and programmed cell death protein 1 (PD-1) (21). However, there is currently a lack of prediction models based on ultrasound radiomic features for assessing MVI risk in HCC patients. Moreover, MRI/CT involve higher costs, longer examination times, and certain contraindications, making them less widely applicable than ultrasound in clinical practice. In contrast, ultrasound is low-cost, convenient, and widely accessible, with clinical guidelines recommending it as a primary method for HCC screening. Therefore, this study developed a random forest prediction model based on preoperative ultrasound radiomic features combined with clinical characteristics to predict MVI risk in HCC patients, aiming to provide an economical, efficient, and non-invasive approach for early identification of MVI positivity in HCC patients. Ultrasound radiomic features encompass shape, intensity, and texture characteristics, which can reflect the complexity of underlying tissue properties. In this study, 10-fold cross-validated LASSO regression was applied to reduce the dimensionality and select features from 1,046 ultrasound radiomic features in the training set, ultimately identifying four highly generalizable ultrasound radiomic features. Wavelet features in radiomics are derived from wavelet decomposition of the original image, enabling a more comprehensive description of image characteristics and improving the ability to interpret and analyze images. All four selected ultrasound radiomic features in this study were wavelet-based, which provide multi-scale information across different frequency ranges and help reveal subtle, hidden structural variations. High-frequency wavelet features primarily reflect information related to tumor morphology, boundary shape, and fine structural details. Among them, wavelet.LLL_lbp.3D.m1_firstorder_Maximum is a wavelet-derived feature that combines wavelet transformation with local binary patterns (LBP). This feature is extracted by first applying wavelet transformation to obtain the low-frequency sub-band, which preserves the main structural information of the image, and then using LBP to capture local texture patterns, potentially aiding in the identification of characteristic HCC textures. Previous studies have shown that wavelet-based radiomic features can effectively predict tumor differentiation grade (19) and the expression status of biomarkers such as CK19 (22), Ki-67 (23), and glypican-3 (GPC3) (24) in HCC research. Furthermore, a study by Witjes et al. (25) found that the expression of CK19, Ki-67, and GPC3 is closely associated with MVI, tumor differentiation, and invasive and metastatic potential in HCC. This suggests that the wavelet features used in our model may be related to the malignant biological phenotype of MVI-positive HCC. However, the specific mechanisms underlying the relationship between ultrasound radiomic features and MVI in HCC have not been fully elucidated. Future studies should integrate multi-omics data to further explore the biological significance of these features. In recent years, with the rapid advancement of data mining and artificial intelligence, machine learning has played an increasingly important role in medical research. The BPNN is one of the widely used neural network models and belongs to the category of deep learning algorithms. It trains a multi-layer feedforward network using the backpropagation gradient descent method, iteratively updating and optimizing the weights of feature variables to minimize prediction error (26,27). For outcome prediction across various diseases, neural networks can identify suitable network structures for learning, demonstrating strong capabilities in nonlinear mapping, scalability, adaptability, and fault tolerance (28,29). In contrast, random forest is a machine learning algorithm based on ensemble learning, which improves model performance by constructing multiple decision trees and aggregating their predictions. It is more suitable for small datasets, does not require complex hyperparameter tuning like BPNN, and exhibits stronger resistance to overfitting and better interpretability (30,31). The results of this study show that the Random Forest model, built using both clinical and ultrasound radiomic features, outperformed the BPNN model (based solely on ultrasound radiomics) and the Nomogram model (based solely on clinical features) in terms of predictive performance, accuracy, and net benefit. This indicates that the integrated model combining clinical indicators and ultrasound radiomics achieves better predictive efficacy compared to single-feature models. Moreover, the Random Forest model demonstrated stronger predictive power and generalization ability relative to other machine learning approaches. We acknowledge that the near-perfect AUC of 0.999 in the training cohort raises concerns about potential overfitting or data leakage. Several factors may contribute to this observation: First, while our sample size (n=224) meets the minimum requirement based on EPV calculations (k=7, EPV=10, p=0.33), it is still relatively small for machine learning models, particularly when extracting 1,046 radiomic features. Second, although we employed LASSO regression for feature selection within the training cohort only and used separate training/test cohorts, some degree of information leakage cannot be entirely ruled out during the feature engineering and preprocessing steps. Third, the Random Forest algorithm, while robust against overfitting through bootstrap aggregation and random feature selection, may still achieve artificially high performance when the number of features approaches or exceeds the number of samples. Importantly, the more modest but still strong performance in the test cohort (AUC =0.908, Brier score =0.117) likely reflects the model’s true generalizability. The performance drop from training to test (AUC: 0.999 to 0.908; Brier score: 0.028 to 0.117) is consistent with the expected optimism bias in model development and suggests that the initial training performance was indeed inflated. This underscores the critical importance of external validation in independent, multi-center cohorts before any clinical implementation. Future studies with larger sample sizes and rigorous external validation are needed to confirm the model’s transportability across different patient populations and ultrasound equipment. This study has several limitations. First, its retrospective design and single-center origin may introduce selection bias. Second, the model requires external validation in independent, multi-center cohorts to confirm its generalizability. Third, the biological interpretability of the selected radiomic features, while supported by indirect evidence, needs direct pathological correlation in future studies. Conclusions We have developed and validated a Random Forest prediction model that integrates clinical characteristics and ultrasound radiomics features for preoperative assessment of MVI in HCC patients. The model achieved an AUC of 0.908 in the test cohort, significantly outperforming both the BPNN and Nomogram models. Three clinical predictors (maximum tumor diameter, AFP, and VEGF) and four wavelet-based ultrasound radiomic features were identified as key contributors. Despite these promising results, several limitations should be acknowledged. First, this was a retrospective, single-center study, which may introduce selection bias. Second, the biological mechanisms underlying the association between selected radiomic features and MVI remain to be elucidated. In conclusion, this model provides a cost-effective, noninvasive approach to support individualized surgical planning for HCC patients. Future studies with larger, multi-center cohorts and prospective designs are warranted to validate its generalizability and clinical utility before implementation in routine practice. Supplementary The article’s supplementary files as Available at https://tcr.amegroups.com/article/view/10.21037/tcr-2026-1-0031/prf